2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle  
12/22/16Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement
Transaction to create NASDAQ-listed pharmaceutical company focused on the development and commercialization of ear, nose, and throat (ENT) products Gregory J. Flesher to be Named President and Chief Executive Officer of the Combined Company BOSTON, Mass., IRVINE, Calif., & REHOVOT, Israel--(BUSINESS WIRE)--Dec. 22, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical comp... 
Download PDFPrinter Friendly Version
09/08/16Tokai Pharmaceuticals Announces Review of Strategic Alternatives
BOSTON--(BUSINESS WIRE)--Sep. 8, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that its Board of Directors has initiated a review of strategic alternatives for the company focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated a... 
Download PDFPrinter Friendly Version
07/29/16Tokai Pharmaceuticals Announces Reduction in Force
BOSTON--(BUSINESS WIRE)--Jul. 29, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it is reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees, under a plan expected to be largely completed by the end of the third quarter of 2016. This ... 
Download PDFPrinter Friendly Version
07/26/16Tokai Pharmaceuticals Announces Clinical Update
Company to Discontinue Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive mCRPC Tokai to Host Conference Call Today at 8:30 AM E.T. BOSTON--(BUSINESS WIRE)--Jul. 26, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it plans to discontinue the ARMOR3-SV cli... 
Download PDFPrinter Friendly Version
06/02/16Tokai Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that management will participate in the following upcoming investor conferences: Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at the Grand Hyatt in New York C... 
Download PDFPrinter Friendly Version
05/18/16Tokai Announces Publication of Three Abstracts on Galeterone at the 2016 ASCO Annual Meeting
Abstracts feature a review of ARMOR2 trial results, ARMOR3-SV trial-in-progress and a review of galeterone’s unique mechanism of action BOSTON--(BUSINESS WIRE)--May 18, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that data related to galeterone will be presented in two posters at th... 
Download PDFPrinter Friendly Version
05/10/16Tokai Pharmaceuticals Reports First Quarter 2016 Financial Results
BOSTON--(BUSINESS WIRE)--May 10, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter ended March 31, 2016. “Over the past quarter we have made significant progress in our clinical development program for galeterone, as we c... 
Download PDFPrinter Friendly Version
05/05/16Tokai Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BOSTON--(BUSINESS WIRE)--May 5, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at 10:40am PT at the Encore at Wynn Las Vegas. ... 
Download PDFPrinter Friendly Version
04/26/16Tokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting
BOSTON--(BUSINESS WIRE)--Apr. 26, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced an oral presentation on galeterone at the 2016 American Urological Association (AUA) Annual Meeting in San Diego. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with ... 
Download PDFPrinter Friendly Version
04/13/16Tokai Announces Presentations on Galeterone at the AACR Annual Meeting 2016
BOSTON--(BUSINESS WIRE)--Apr. 13, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that two presentations on galeterone will be made during poster sessions held at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. Galeterone, Tokai’s lead product candida... 
Download PDFPrinter Friendly Version
04/06/16Tokai Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
BOSTON--(BUSINESS WIRE)--Apr. 6, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that management will present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 1:40pm ET at The Westin Grand Central in New York City. A live webcast of the presenta... 
Download PDFPrinter Friendly Version
03/30/16Tokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients
BOSTON--(BUSINESS WIRE)--Mar. 30, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it has begun dosing patients in an expansion arm of ARMOR2, the company’s ongoing Phase 2 clinical trial of galeterone, to further explore the safety and clinical activity of galeterone in metastatic ... 
Download PDFPrinter Friendly Version
03/21/16Tokai Strengthens Development Team Through the Addition of Kelly Lindert, M.D., as Executive Vice President and Head of Development
BOSTON--(BUSINESS WIRE)--Mar. 21, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it has strengthened its development team with the addition of Kelly A. Lindert, M.D., as Executive Vice President and Head of Development. “Kelly is joining Tokai’s senior leadership team at an im... 
Download PDFPrinter Friendly Version
03/10/16Tokai Pharmaceuticals Reports Full Year 2015 Financial Results
Company highlights ARMOR3-SV progress and expansion of galeterone development program BOSTON--(BUSINESS WIRE)--Mar. 10, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the year ended December 31, 2015. “We have made subst... 
Download PDFPrinter Friendly Version
01/08/16Tokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium
SAN FRANCISCO--(BUSINESS WIRE)--Jan. 8, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced the presentation of new data describing the novel mechanism by which galeterone degrades the androgen receptor. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men wit... 
Download PDFPrinter Friendly Version
01/07/16Tokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program
Top-line Data for ARMOR3-SV Expected by Mid-2017 Expanded Clinical Program for Galeterone Planned for First Half of 2016 BOSTON--(BUSINESS WIRE)--Jan. 7, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) today provided an update on its clinical development program evaluating galeterone in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). ARMOR3-SV Update Tokai is enrolling patients in its ... 
Download PDFPrinter Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet